ARK Genomic Revolution ETF
Cboe Consolidated Listings:ARKG

  • LAST PRICE
    22.66
  • TODAY'S CHANGE (%)
    0.00 (0.00%)
  • Bid / Lots
    23.00/ 1
  • Ask / Lots
    23.80/ 2
  • Open / Previous Close
    --- / 22.66
  • Day Range
    ---
  • 52 Week Range
    22.33
    34.37
  • Volume
    2,278
  • Overall Morningstar Rating
    out of 268 funds

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Daily Premium/Discount

Bar Graph.See accessible table below
ETFs trading at a price higher than its Net Asset Value (NAV) is said to be trading at a premium, while those trading at price lower than its NAV is said to be at a discount. By showing the daily premium/discount percentage, we can see the trend in market sentiments, regarding the value of an ETF over time.

Holdings Diversification

Asset Class
US Stock		91.1%
Non-US Stock		8.7%
Cash		0.2%
Convertible		0
Non-US Bond		0
Other		0
Sectors
Healthcare99.8%
Basic Mat.0
Communication Services0
Consumer Cyclical0
Consumer Defensive0
Energy0
Financial Serv.s0
Industrials0
Real Estate0
Technology0
Utilities0
Geographic Region
United States		91.3%
Canada		0.7%
Latin America		0
Africa		0
Europe		0
Asia/Oceania		0
As of 2024-10-31

Top 10 Holdings

Company NamePositionAllocation
Allocation
1 Month Change
Market Value
TWST
Twist Bioscience Corp
Long
8.7%
+0.48%
$107.5M
RXRX
Recursion Pharmaceuticals Inc Class A
Long
7.0%
+0.48%
$87.5M
CRISPR Therapeutics AG
Long
7.0%
+0.48%
$87.2M
CDNA
CareDx Inc
Long
5.1%
-0.70%
$63.3M
ADPT
Adaptive Biotechnologies Corp
Long
4.7%
+0.48%
$58.2M
VCYT
Veracyte Inc
Long
4.6%
+0.48%
$57.5M
IONS
Ionis Pharmaceuticals Inc
Long
4.3%
+0.48%
$53.9M
NRIX
Nurix Therapeutics Inc Ordinary Shares
Long
4.1%
+0.29%
$50.7M
NTRA
Natera Inc
Long
3.8%
+0.48%
$47.2M
TXG
10x Genomics Inc Ordinary Shares - Class A
Long
3.8%
+0.48%
$47.0M
As of 2024-11-11

Reports

  • 11/10/24

    Morningstar ETF Report

    The Morningstar ETF Report offers in-depth analyst research on exchange-traded funds to help you evaluate these investments and how they fit within a portfolio.

Morningstar Ratings

Time HorizonStar Rating
Overall Rating
3 Year Rating
5 Year Rating
10 Year Rating
As of 2024-10-31

Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.

Style Box is calculated only using the long position holdings of the portfolio.

ETF Profile
Best Fit Index
NASDAQ Health Care GR EUR
Category
Health
Sponsor
ARK Investment Management LLC
Inception
October 31, 2014
As of 2024-10-31

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Holding Details
Total Net Assets$1.2B
Shares Out.51.4M
Net Asset Value (NAV)$22.65
Prem/Discount to NAV0.04%
P/E Ratio---
Dividend Yield---
Dividend per Share---
Ex-Dividend Date---
Dividend Payment Date---
Beta---
Morningstar Investment StyleHealth
Equity Style
Small Cap Blend
Credit Quality / Duration
---
Fees & Expenses
Actual Management Fee0.75%
Actual Mgmt. Expense Ratio (MER)0.75%